Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

The Institute of Cancer Research, London, is seeking partners to continue the development of a breast cancer gene signature for predicting resistance/ sensitivity to aromatase inhibitors and/or CDK4/6 ...

Our preliminary data revealed that epigenetic regulation is involved in the resistance to one chemotherapeutic, CDK4/6 inhibitor. We determine how an altered epigenetic landscape contributes to the ...

"Our study reveals that continuing CDK4/6 inhibitors with ET [endocrine therapy ... without endocrine resistance or visceral crisis," the authors concluded. "It underscores the need for tailored ...

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

Starr Hazard, Gary T. Hardiman, Renée de Leeuw, Karen E. Knudsen, and J. Alan Diehl (2019) SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv. 5: eaax6352 * ...